# Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

> **NCT00441883** · PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 176 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension
- Pigmentary Glaucoma
- Pseudoexfoliative Glaucoma

## Interventions

- **DRUG:** PF-03187207 and Latanoprost Vehicle
- **DRUG:** Latanoprost 0.005% and PF-03187207 Vehicle

## Key facts

- **NCT ID:** NCT00441883
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-02
- **Final completion:** 2008-07
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2020-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441883, "Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00441883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*